Glucagon-Like Peptide-1 is used as a Effector in the hormonal control of insulin secretion. The peptide fragment is secreted from the lower small intestine. Its action is mediated by receptors expressed by the endocrine pancreatic B-cells.
Glucagon-Like Peptide (GLP) I Amide Fragment 7-36 human has been used as a GLP-1 receptor agonist:
- in lysate transfer cyclic adenosine monophosphate (cAMP) assay to test its effect on adenylyl cyclase activity
- to pre-treat the human umbilical vein endothelial cells (HUVECs) to monitor its effect on hyperpermeability in endothelial cell (EC) monolayers and changes with the actin cytoskeleton
- to test its inhibitory effect on vascular endothelial growth factor-A (VEGFA) based vasodilation in rat mesenteric arteries
DiabetesII-notyetanapprovedapplication
Glucagon-like peptide 1 (GLP-1) peptide is obtained from proglucagon and is metabolically inactive. However, it is processed to two smaller amide forms, namely GLP-1 (7-37) amide and GLP-1 (7-36) amide. It is a natural gastrointestinal peptide.
GLP-1 (glucagon-like peptide 1) (7-36) amide is a potent insulinotropic peptide, which initiates the glucose-induced insulin release after meals or oral glucose intake. It has an anti-diabetogenic effect and thus, might have use in the treatment of non-insulin dependent diabetes mellitus.
Glucagon-Like Peptide (GLP) I (7-36), amide is a physiological incretin hormone that is released after nutrient intake from the lower gut and stimulates insulin secretion at elevated plasma glucose concentrations. Exogenous GLP-1 (7-36 amide) is an effective means of normalizing fasting plasma glucose concentrations in poorly-controlled Type 2 diabetic subjects[3]. Exogenously administered GLP-1-(7–36)amide is extremely labile in vivo, with more than 80% being cleaved into GLP-1-(9–36)amide after sc or iv administration[4].
